Celera, SomaLogic Pen Multi-Year Proteomics Deal | GenomeWeb

NEW YORK, Aug 16. – Proteomics company SomaLogic said Thursday it had signed a multi-year deal to provide Celera with early access to its aptamers and aptamer arrays.

In exchange, SomaLogic will receive access to Celera’s sequence data and proteins with which it can develop additional aptamers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.